RGLS

Regulus Therapeutics Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website regulusrx.com
Employees(FY) 29
ISIN US75915K3095

Performance

+1.65%

-18.0%

-21.15%

-33.51%

-22.15%

YTD

-3.15%

Profile

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of RGLS 2025-02-03

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 30 and the Technical Score at 33, both indicating weak performance. Although the Oscillators Score is neutral at 53, the overall outlook remains cautious due to the low scores in the other categories.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of RGLS

Stock Rank

Recent News & Updates

2023-11-09 03:32
Regulus: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-09 03:05
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates(Prnewswire)
2023-11-01 20:00
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2023-10-18 20:00
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Prnewswire)
2023-09-19 19:00
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Yahoo Finance)
2023-09-12 20:00
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Yahoo Finance)
2023-09-04 20:00
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences(Yahoo Finance)
2023-08-24 07:33
Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?(Yahoo Finance)
2023-08-23 01:04
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance(Yahoo Finance)
2023-08-22 20:00
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023(Yahoo Finance)
2023-08-08 04:43
Regulus: Q2 Earnings Snapshot(Yahoo Finance)
2023-08-08 04:05
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates(Yahoo Finance)
2023-08-01 20:00
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference(Yahoo Finance)
2023-07-17 20:00
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference(Yahoo Finance)
2023-06-26 20:00
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Yahoo Finance)
2023-06-22 20:00
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors(Yahoo Finance)
2023-06-19 20:00
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital(Yahoo Finance)
2023-06-11 20:00
Regulus Therapeutics Strengthens Research & Development Leadership(Yahoo Finance)
2023-05-15 20:00
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Yahoo Finance)
2023-05-11 04:18
Regulus: Q1 Earnings Snapshot(Yahoo Finance)
2023-05-11 04:05
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates(Yahoo Finance)
2023-04-12 20:00
Regulus Therapeutics Announces $15 Million Private Placement of Equity(Yahoo Finance)
2023-04-12 04:05
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)(Yahoo Finance)
2023-03-23 04:52
Regulus: Q4 Earnings Snapshot(Yahoo Finance)
2023-03-23 04:05
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates(Yahoo Finance)
2023-02-08 19:00
Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference(Yahoo Finance)
2023-01-13 03:05
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Yahoo Finance)
2023-01-08 17:01
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics(Yahoo Finance)
2022-12-11 19:00
Regulus Therapeutics Announces Resignation of Board Member(Yahoo Finance)
2022-11-29 04:43
13 Best Biotech Penny Stocks To Buy Now(Yahoo Finance)

Page 2 of 5

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.